As of November 6, 2026, Lipocine Inc. is a publicly traded company (Nasdaq: LPCN); its largest reported holder is Squadron Master Fund LP, with 9.8% on Schedule 13G/A of August 14, 2026, then Squadron Capital Management LLC (9%). The largest insider holding is John W. Higuchi, a director, with 241,365 shares (2.2% of shares outstanding), per Form 4 of October 1, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Lipocine Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lipocine Inc. a real, registered company?
- Lipocine Inc. files with the SEC under CIK 1535955 (its SEC filings).
- Its shares are listed under the ticker LPCN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Salt Lake City, X1, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lipocine Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Spyros Papapetropoulos, Director (Form 8-K filed 2026-04-21). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Squadron Master Fund LP (filed 2026-08-14).
Who are Lipocine Inc.'s owners and officers?
Lipocine Inc.: incorporated in Delaware; business address in Salt Lake City, X1; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Squadron Master Fund LP | 9.8% |
| Schedule 13G, 2026-05-15 | Ikarian Capital, LLC | 6.3% |
| Schedule 13G/A, 2026-05-15 | Squadron Master Fund LP | 6.2% |
| Schedule 13G/A, 2026-02-17 | Squadron Master Fund LP | 9.5% |
| Schedule 13G, 2025-12-23 | Squadron Capital Management LLC | 9% |
Questions about who owns Lipocine Inc.
Who owns Lipocine Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Lipocine Inc.: Squadron Master Fund LP (9.8%, Schedule 13G/A, filed 2026-08-14), Squadron Capital Management LLC (9%, Schedule 13G, filed 2025-12-23) and Ikarian Capital, LLC (6.3%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Lipocine Inc.?
By the share each holder's latest filing reports, the largest holders of Lipocine Inc. on this page are Squadron Master Fund LP (9.8%), Squadron Capital Management LLC (9%) and Ikarian Capital, LLC (6.3%).
When did Squadron Master Fund LP buy into Lipocine Inc.?
The filings give report dates, not purchase dates. The earliest filing from Squadron Master Fund LP on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.5%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lipocine Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lipocine Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lipocine Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-21 | Spyros Papapetropoulos | Director | departed | |
| Form 8-K, 2026-04-21 | Spyros Papapetropoulos | departed |
Which insiders own Lipocine Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 241,365 shares (2.2% of shares outstanding) (Form 4, 2026-10-01).
- , the chief executive and a director: 160,679 shares (1.5% of shares outstanding) (Form 4, 2026-04-06).
Shares outstanding: 11,073,439 as of 2026-11-04, from the company's latest SEC cover page.
How much has Lipocine Inc. raised?
No fundraising or offering filing from Lipocine Inc. is on file with us.
Keep reading
More on Lipocine Inc. and the records around it.
Lipocine Inc. elsewhere on the record
- Leadership changes Aug 2026
Companies that share a holder
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lipocine